Lisdexamfetamine, marketed as Vyvanse, is a scheduled drug approved in Canada for managing Attention-Deficit/Hyperactivity Dysfunction in children and people. It's functions as a prodrug, meaning it’s inactive until metabolized by the body, providing dextroamphetamine slowly over an extended period